Nonalcoholic fatty liver disease and reduced serum vitamin D3 levels

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 4, 2013, Pages 217-228

  Targher, Giovanni ^a   Scorletti, Eleonora ^b   Mantovani, Alessandro ^a   Byrne, Christopher D ^b,c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 DEHYDROCHOLESTEROL; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ASPARTATE AMINOTRANSFERASE; CALCIFEDIOL; CALCITRIOL; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLECALCIFEROL; COLLAGEN; COLLAGEN TYPE 1; CORTICOSTEROID; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; GLUCAGON LIKE PEPTIDE 1; GLUCOSE TRANSPORTER 4; INSULIN; INTERLEUKIN 6; INTERLEUKIN 8; KETOCONAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; PARATHYROID HORMONE; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D RECEPTOR;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID SYNTHESIS; CARDIOMETABOLIC RISK; CELL ACTIVITY; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; EPIDEMIOLOGY; FATTY ACID METABOLISM; FIBROBLAST; HOSPITAL PATIENT; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER BIOPSY; LIVER PROTECTION; MACROPHAGE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SMALL INTESTINE; SUPPLEMENTATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

ADIPOSE TISSUE; BILE; BILE ACIDS AND SALTS; CHOLECALCIFEROL; FATTY LIVER; HUMANS; IMMUNOLOGIC FACTORS; INSULIN RESISTANCE; INTESTINES; MODELS, BIOLOGICAL; RISK FACTORS; SIGNAL TRANSDUCTION; VITAMIN D DEFICIENCY;

EID: 84880420937     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2013.0044     Document Type: Review

References (60)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.
2. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-1350.
3. Targher G, Chonchol M, Zoppini G, et al. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? J Hepatol 2011;54:1020-1029.
4. Targher G, Byrne CD. Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013;98:483-495.
5. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357: 266-281.
6. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010;95:471-478.
7. Targher G, Pichiri I, Lippi G. Vitamin D, thrombosis, and hemostasis: More than skin deep. Semin Thromb Hemost 2012; 38:114-124.
8. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC. November 30, 2010. http://www.iom.edu/Reports/ 2010/Dietary-Reference-Intakes-for-Calcium-and- Vitamin-D .aspx/. Accessed May 17, 2013.
9. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22: 477-501.
10. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25- hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008;88:1519- 1527.
11. Cigolini M, Miconi V, Soffiati G, et al. Hypovitaminosis D among unselected medical inpatients and outpatients in Northern Italy. Clin Endocrinol (Oxf) 2006;64:475.
12. Vidailhet M, Mallet E, Bocquet A, et al.; Comité de nutrition de la Socie'té française de pe'diatrie. Vitamin D: Still a topical matter in children and adolescents. A position paper by the Committee on Nutrition of the French Society of Paediatrics. Arch Pediatr 2012;19:316-328.
13. Arabi A, El Rassi R, El-Hajj Fuleihan G. Hypovitaminosis D in developing countries - prevalence, risk factors and outcomes. Nat Rev Endocrinol 2010;6:550-561.
14. Pittas AG, Lau J, Hu FB, et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and metaanalysis. J Clin Endocrinol Metab 2007;92:2017-2029.
15. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 2010;152:307-314.
16. Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010;33: 1379-1381.
17. George PS, Pearson ER, Witham MD, et al. Effect of vitamin D supplementation on glycaemic control and insulin resistance: A systematic review and meta-analysis. Diabet Med 2012;29:e142-e150.
18. Liangpunsakul S, Chalasani N. Serum vitamin D concentrations and unexplained elevation in ALT among us adults. Dig Dis Sci 2011;56:2124-2129.
19. Kayaniyil S, Reinhold V, Harris SB, et al. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab 2011;96:168-175.
20. Katz K, Brar PC, Parekh N, et al. Suspected nonalcoholic fatty liver disease is not associated with vitamin D status in adolescents after adjustment for obesity. J Obes 2010;2010: 496829.
21. Barchetta I, Angelico F, Del Ben M, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011;9:85.
22. Jablonski KL, Jovanovich A, Holmen J, et al. Low 25- hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2013; Feb 13; doi: 10.1016/j.numecd.2012.12.006 [Epub ahead of print].
23. Nseir W, Taha H, Khateeb J, et al. Fatty liver is associated with recurrent bacterial infections independent of metabolic syndrome. Dig Dis Sci 2011;56:3328-3334.
24. Rhee EJ, Kim MK, Park SE, et al. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr J 2013; Feb 13; doi: 10.1507/endocrj.EJ12-0387 [Epub ahead of print].
25. Foster T, Chalasani NP, Liangpunsakul S, et al. The association of serum vitamin D concentrations and nonalcoholic fatty liver disease (NAFLD): The Multi-Ethnic Study of Atherosclerosis. Hepatology 2011;54(Suppl 4):1129A- 1130A.
26. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007;17:517-524.
27. Manco M, Ciampalini P, Nobili V. Low levels of 25-hydroxyvitamin D3 in children with biopsy-proven nonalcoholic fatty liver disease. Hepatology 2010;51:2229.
28. Dasarathy J, Periyalwar P, Allampati S, et al. Hypovitaminosis D associated with more advanced non-alcoholic fatty liver disease. Hepatology 2012;56(Suppl 1):889A- 890A.
29. Orsi CM, Lynch JL, Hale DE. Magnetic resonance spectroscopy quantification of NAFLD in obese adolescents on vitamin D therapy. Endocr Rev 2012;33(03-Meeting Abstracts): MON-240.
30. Weber K, Erben RG. Differences in triglyceride and cholesterol metabolism and resistance to obesity in male and female vitamin D receptor knockout mice. J Anim Physiol Anim Nutr (Berl) 2012; doi: 10.1111/j.1439-0396.2012.01308.x, Apr 30 [Epub ahead of print].
31. Geier A. Shedding new light on vitamin D and fatty liver disease. J Hepatol 2011;55:273-275.
32. Barchetta I, Carotti S, Labbadia G, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: Relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012;56:2180-2187.
33. Roth CL, Elfers CT, Figlewicz DP, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012;55:1103-1111.
34. Miura K, Seki E, Ohnishi H, et al. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010; 2010:362847.
35. Fabbrini E, Mohammed BS, Magkos F, et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008;134:424-431.
36. Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 2005;115:1139-1142.
37. Belenchia AM, Tosh AK, Hillman LS, Peterson CA. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: A randomized controlled trial. Am J Clin Nutr 2013; Feb 13 [Epub ahead of print].
38. Wamberg L, Cullberg KB, Rejnmark L, et al. Investigations of the anti-inflammatory effects of vitamin d in adipose tissue: Results from an in vitro study and a randomized controlled trial. Horm Metab Res 2013; Jan 15 [Epub ahead of print].
39. Gao D, Trayhurn P, Bing C. 1,25-Dihydroxyvitamin D(3) inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes (Lond) 2012; Apr 17 [Epub ahead of print].
40. Manna P, Jain SK. Vitamin D up-regulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-gamma-lyase (CSE) activation and H2S formation in 3T3L1 adipocytes. J Biol Chem 2012;287: 42324-42332.
41. Masuda S, Okano T, Osawa K, et al. Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis. J Nutr Sci Vitaminol (Tokyo) 1989;35:225-234.
42. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol 2013;368:17-29.
43. Kong B, Wang L, Chiang JY, et al. Mechanism of tissuespecific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012;56: 1034-1043.
44. Chow EC, Maeng HJ, Liu S, et al. 1alpha,25-Dihydroxyvitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm Drug Dispos 2009;30:457-475.
45. Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7-alpha-hydroxylase gene expression. Hepatology 2009;49:297-305.
46. Chiang JY. Bile acids: Regulation of synthesis. J Lipid Res 2009;50:1955-1966.
47. Schmidt DR, Holmstrom SR, Fon TK, et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010;285:14486-14494.
48. Li T, Owsley E, Matozel M, et al. Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 2010;52:678-690.
49. Han S, Li T, Ellis E, et al. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol Endocrinol 2010;24:1151-1164.
50. Jain R, von Hurst PR, Stonehouse W, et al. Association of vitamin D receptor gene polymorphisms with insulin resistance and response to vitamin D. Metabolism 2012;61:293- 301.
51. Eelen G, Verlinden L, Meyer MB, et al. 1,25-Dihydroxyvitamin D(3) and the aging-related Forkhead Box O and sestrin proteins in osteoblasts. J Steroid Biochem Mol Biol 2012; Sep 16 [Epub ahead of print].
52. Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 2011;13:729- 738.
53. Liu HY, Han J, Cao SY, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: Inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem 2009;284:31484- 31492.
54. Aranha MM, Cortez-Pinto H, Costa A, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008;20:519-525.
55. Bechmann LP, Kocabayoglu P, Sowa JP, et al. Free fatty acids repress SHP activation and adiponectin counteracts bile acid induced liver injury in super-obese patients with NASH. Hepatology 2013; Jan 8 [Epub ahead of print].
56. Schreuder TC, Marsman HA, Lenicek M, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010;298:G440-G445.
57. Potter JJ, Liu X, Koteish A, et al. 1,25-dihydroxyvitamin D3 and its nuclear receptor repress human alpha(1) (I) collagen expression and type I collagen formation. Liver Int 2013; Jan 25 [Epub ahead of print].
58. Abramovitch S, Dahan-Bachar L, Sharvit E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011;60:1728-1737.
59. Nakano T, Cheng YF, Lai CY, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 2011;55:415-425.
60. Sung CC, Liao MT, Lu KC, et al. Role of vitamin D in insulin resistance. J Biomed Biotechnol 2012;2012:634195.